Examples of Biogen International in a sentence
The net book values of the TYSABRI and TECFIDERA assets as of September 30, 2018, were $2,073.6 million and $262.6 million, respectively.TECFIDERA License RightsIn January 2017 we entered into a settlement and license agreement among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma and certain related parties, which was effective as of February 1, 2017.
Biogen International GmbH is the owner of the ’376 patent by virtue of assignment.
Biogen International GmbH is the owner of the ’999 patent by virtue of assignment.
Plaintiff Biogen International GmbH is a Swiss corporation with its principal place of business in Zug, Switzerland at Landis + Gyr-Strasse 3, 6300 Zug, Switzerland.
As a result, Biogen International and its affiliates have sole authority over, and exclusive worldwide rights to, the development, manufacturing and commercialisation of Tysabri.
The Contributor is a party to the Settlement and License Agreement dated as of 17 January 2017 among Biogen Swiss Manufacturing GmbH (“ Biogen Switzerland”), Biogen International Holding Ltd.
The net book value of this asset as of March 31, 2017 was $2,418.6 million.In January 2017 we entered into a settlement and license agreement among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma A/S (Forward Pharma) and certain related parties, which was effective as of February 1, 2017.
Biogen International GmbH By:______________________________________ [signature] Name: Title: .
Xxxxxxx Email: xxxxxxx@xxxxxx.xxx xxxxxxxx@xxxxxx.xxx if to Aditech, to: Aditech Pharma AG c/o Domanda Verwaltungs GmbH Xxxxxxxxxxxxx 00 6302 Zug Attention: Xxxxxxx Xxxxxxxxxxxx Email: xx@xxxxxxxxxxxxx.xxx with a copy to (which copy does not constitute notice): Xxxxxxxxx Lawfirm P/S Xxxxxx Xxxxxxxx 00 Attention: Xxxxxxxxx Xxxxxxxx Guldmann Email: xxx@xxxxxxxxx.xx In the case of any Notice, with a copy to: Biogen Swiss Manufacturing GmbH Biogen International Holding Ltd.
BiogenOn December 18, 2019, the Company and Biogen International GmbH (“Biogen”) entered into a License and Collaboration Agreement (the “Biogen Agreement”), under which the Company granted Biogen a worldwide, royalty-bearing, exclusive, with the right to sublicense, license (“Exclusive License”) to develop and commercialize CB 2782-PEG and other anti-C3 proteases for potential treatment of dry age-related macular degeneration (“AMD”) and other disorders.